SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Background: Currently, the association between sodium-glucose cotransporter 2 inhibitor (SGLT-2i) and malignancy risk has yet to be fully elucidated. This meta-analysis aimed to determine the relationship between SGLT-2i and malignancy risk in type 2 diabetes (T2D) patients. Methods: We searched Pub...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Nanjing, Shi, Yetan, Xu, Jingsi, Si, Yuexiu, Yang, Tong, Zhang, Mengting, Ng, Derry Minyao, Li, Xiangyuan, Xie, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215266/
https://www.ncbi.nlm.nih.gov/pubmed/34164370
http://dx.doi.org/10.3389/fpubh.2021.668368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215266/
https://www.ncbi.nlm.nih.gov/pubmed/34164370
http://dx.doi.org/10.3389/fpubh.2021.668368

Ejemplares similares